Institutional investors now manage portfolios by treating inadequate environmental, social, and governance strategies as material financial liabilities rather than mere corporate social responsibility gestures. This seismic shift marks the end of an era where pharmaceutical companies could rely on
Rising operational costs and increased patient acquisition expenses are forcing behavioral health providers to prioritize sustainable efficiency over broad geographic reach. The era of the rapid "land grab" that dominated the early 2020s has given way to a more disciplined approach where investors
Beam Therapeutics’ BEAM-304 is in a Phase 1/2 trial designed to address different mutations in the phenylalanine hydroxylase (PAH) gene that cause phenylketonuria (PKU). For developers, this raises a practical licensing question: how can they support several customized treatments without making
Hims & Hers now faces a potential peptide opportunity with a changed enforcement outlook but no new clinical evidence. Health and Human Services Secretary Robert F. Kennedy Jr. has introduced a policy under which HHS would refrain from enforcement against specified providers compounding six
The current practice of requiring separate scientific assessments for the same product in fifty-four different countries discourages investment and increases the cost of doing business in Africa. This structural inefficiency has long kept the continent in a state of dependency, forcing it to import
Safe and reliable protein sources remain a foundational requirement for global food security, requiring a stable and unpolluted supply chain from start to finish. The persistence of Salmonella as a ubiquitous pathogen presents a complex challenge for the poultry sector, as specific strains like
